Michael Gelband’s Verrica Pharmaceuticals VRCA Stock Holding History

Michael Gelband’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-18,613	Closed	-$270K	–	2102
2024 Q3	$270K	Buy	+18,613	New	+$838K	﹤0.01%	1390

Other funds holding VRCA

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Michael Gelband's VRCA Position: Q4 2024 in Review

Michael Gelband sold out of Verrica Pharmaceuticals (VRCA) in Q4 2024, closing a stake of 18,613 shares — an estimated $270K sold.

Michael Gelband first reported a position in VRCA in Q3 2024 and held it in 1 quarter. The position peaked at $270K in Q3 2024. 81 funds tracked by Wall St. Rank hold VRCA as of Q4 2024.

Michael Gelband reported no remaining Verrica Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Michael Gelband sold 18,613 Verrica Pharmaceuticals shares in Q4 2024, an estimated $270K.
Michael Gelband first reported a position in Verrica Pharmaceuticals in Q3 2024 and held it in 1 quarter.
Michael Gelband's Verrica Pharmaceuticals position peaked at $270K in Q3 2024.
81 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.